Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.
Publication
, Journal Article
Assimos, DG
Published in: J Urol
August 2013
Duke Scholars
Published In
J Urol
DOI
EISSN
1527-3792
Publication Date
August 2013
Volume
190
Issue
2
Start / End Page
570 / 571
Location
United States
Related Subject Headings
- Urology & Nephrology
- Sodium Chloride Symporter Inhibitors
- Nephrolithiasis
- Male
- Hypercalciuria
- Humans
- Female
- Bone Diseases, Metabolic
- Bone Density Conservation Agents
- Alendronate
Citation
APA
Chicago
ICMJE
MLA
NLM
Assimos, D. G. (2013). Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. J Urol, 190(2), 570–571. https://doi.org/10.1016/j.juro.2013.04.103
Assimos, Dean G. “Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.” J Urol 190, no. 2 (August 2013): 570–71. https://doi.org/10.1016/j.juro.2013.04.103.
Assimos DG. Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. J Urol. 2013 Aug;190(2):570–1.
Assimos, Dean G. “Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.” J Urol, vol. 190, no. 2, Aug. 2013, pp. 570–71. Pubmed, doi:10.1016/j.juro.2013.04.103.
Assimos DG. Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. J Urol. 2013 Aug;190(2):570–571.
Published In
J Urol
DOI
EISSN
1527-3792
Publication Date
August 2013
Volume
190
Issue
2
Start / End Page
570 / 571
Location
United States
Related Subject Headings
- Urology & Nephrology
- Sodium Chloride Symporter Inhibitors
- Nephrolithiasis
- Male
- Hypercalciuria
- Humans
- Female
- Bone Diseases, Metabolic
- Bone Density Conservation Agents
- Alendronate